5 Small Cap Stocks with the Highest Upside Potential

3. Compass Pathways (NASDAQ:CMPS)

Average Upside Potential: 102.77%

Compass Pathways (NASDAQ:CMPS) is one of the small cap stocks with the highest upside potential. On April 24, Compass Pathways announced that the US FDA granted a rolling review for its NDA and selected COMP360 for the Commissioner’s National Priority Voucher/CNPV program. COMP360 is a proprietary synthetic psilocybin formulation designed for patients with treatment-resistant depression/TRD.

The CNPV designation provides the company with enhanced regulatory communication and a significantly shortened review timeline of one to two months once the application is filed, though the drug must still meet all standard FDA requirements for safety and efficacy. The decision is supported by positive data from two large Phase 3 clinical trials involving over 1,000 participants. These trials demonstrated that COMP360 could produce clinically meaningful effects as quickly as one day after administration, with results lasting at least six months for many patients.

The safety profile indicated that most adverse events were mild to moderate and typically resolved within 24 hours. The CEO emphasized that this regulatory progress validates the urgent need for innovation in the mental health field, particularly for the estimated 4 million people in the US living with TRD. As the most advanced company in the field of classic psychedelics, Compass Pathways (NASDAQ:CMPS) is currently preparing for the commercial launch of COMP360.

Compass Pathways (NASDAQ:CMPS) is a biotech company focused on developing psychedelic treatments for mental health issues. Its flagship drug candidate COMP360 is being developed as a solution for treatment-resistant depression as well as post-traumatic stress disorder.